Running Title; B7-H1/CD80 pathway in T cell tolerance

[1]  Loise M. Francisco,et al.  PD-L1 regulates the development, maintenance, and function of induced regulatory T cells , 2009, The Journal of experimental medicine.

[2]  L. Mayer,et al.  Suppression of Th1 and Th17, but not Th2, responses in a CD8+ T cell-mediated model of oral tolerance , 2009, Mucosal Immunology.

[3]  Loise M. Francisco,et al.  Intestinal Tolerance Is Converted to Autoimmune Enteritis upon PD-1 Ligand Blockade1 , 2009, The Journal of Immunology.

[4]  Lieping Chen,et al.  PD‐1 ligands expressed on myeloid‐derived APC in the CNS regulate T‐cell responses in EAE , 2008, European journal of immunology.

[5]  G. Trinchieri,et al.  Plasmacytoid dendritic cells mediate oral tolerance. , 2008, Immunity.

[6]  G. Freeman,et al.  Interaction of human PD-L1 and B7-1. , 2008, Molecular immunology.

[7]  G. Zhu,et al.  B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. , 2008, Blood.

[8]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[9]  D. Getnet,et al.  Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. , 2007, Blood.

[10]  Lieping Chen,et al.  Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. , 2007, Blood.

[11]  M. Kubo,et al.  Involvement of the Programmed Death-1/Programmed Death-1 Ligand Pathway in CD4+CD25+ Regulatory T-Cell Activity to Suppress Alloimmune Responses , 2007, Transplantation.

[12]  J. Franklyn,et al.  Tag SNP screening of the PDCD1 gene for association with Graves’ disease , 2007, Clinical endocrinology.

[13]  Yongliang Zhang,et al.  Regulation of T cell activation and tolerance by PDL2. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Freeman,et al.  Tissue expression of PD-L1 mediates peripheral T cell tolerance , 2006, The Journal of experimental medicine.

[15]  G. Zhu,et al.  Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. , 2006, The Journal of clinical investigation.

[16]  T. Okazaki,et al.  The PD-1-PD-L pathway in immunological tolerance. , 2006, Trends in immunology.

[17]  S. Khoury,et al.  Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.

[18]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[19]  Jae-Hoon Chang,et al.  CD8α–11b+ dendritic cells but not CD8α+ dendritic cells mediate cross-tolerance toward intestinal antigens , 2005 .

[20]  L. Prokunina-Olsson,et al.  A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. , 2005, Arthritis and rheumatism.

[21]  C. Drake,et al.  B and T Lymphocyte Attenuator Exhibits Structural and Expression Polymorphisms and Is Highly Induced in Anergic CD4+ T Cells 1 , 2005, The Journal of Immunology.

[22]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[23]  T. Okazaki,et al.  Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4 , 2005, Nature Immunology.

[24]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[25]  C. Drake,et al.  Role of LAG-3 in regulatory T cells. , 2004, Immunity.

[26]  G. Freeman,et al.  PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[27]  C. June,et al.  SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 , 2004, The Journal of Immunology.

[28]  Linrong Lu,et al.  Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Lieping Chen.  Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity , 2004, Nature Reviews Immunology.

[30]  G. Zhu,et al.  B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. , 2004, Immunity.

[31]  D. Sansom,et al.  CD86 and CD80 Differentially Modulate the Suppressive Function of Human Regulatory T Cells1 , 2004, The Journal of Immunology.

[32]  M. Kitajima,et al.  Programmed death-1–programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen , 2004, Transplantation.

[33]  J. Allison,et al.  B7 Expression on T Cells Down-Regulates Immune Responses through CTLA-4 Ligation via R-T Interactions1 , 2004, The Journal of Immunology.

[34]  S. Husby,et al.  Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. , 2003, Tissue antigens.

[35]  G. Zhu,et al.  Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. , 2003, The Journal of clinical investigation.

[36]  G. Freeman,et al.  Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 , 2003, The Journal of Immunology.

[37]  R. Jonsson,et al.  A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans , 2002, Nature Genetics.

[38]  F. Powrie,et al.  CTLA‐4 expression on antigen‐specific cells but not IL‐10 secretion is required for oral tolerance , 2002, European journal of immunology.

[39]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[40]  G. Zhu,et al.  Immunoglobulin fusion proteins as a tool for evaluation of T-cell costimulatory molecules , 2002, Molecular biotechnology.

[41]  V. Singh,et al.  Distinct Role of CD80 and CD86 in the Regulation of the Activation of B Cell and B Cell Lymphoma* , 2002, The Journal of Biological Chemistry.

[42]  Aaron J. Johnson,et al.  Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. , 2002, The Journal of clinical investigation.

[43]  T. Okazaki,et al.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Kehren,et al.  Oral Administration of Hapten Inhibits In Vivo Induction of Specific Cytotoxic CD8+ T Cells Mediating Tissue Inflammation: A Role for Regulatory CD4+ T Cells1 , 2000, The Journal of Immunology.

[45]  G. Zhu,et al.  Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway , 2000, Nature Medicine.

[46]  A. Sharpe,et al.  Mutual regulation between B7-1 (CD80) expressed on T cells and IL-4. , 1999, Journal of immunology.

[47]  H. Weiner,et al.  CTLA-4 is required for the induction of high dose oral tolerance. , 1998, International immunology.

[48]  G. Freeman,et al.  Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[49]  G. Zhu,et al.  Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. , 2004, Blood.

[50]  H. Weiner,et al.  Oral tolerance , 2003, Immunologic research.